Single Nucleotide Polymorphism of <italic>GSTP1</italic> and Pathological Complete Response in Locally Advanced Rectal Cancer Patients Treated with Neoadjuvant Concomitant Radiochemotherapy

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2018 Oct 13

PMID 30309213

Citations 3

Authors

Luca Nicosia

Giovanna Gentile

Chiara Reverberi

Giuseppe Minniti

Maurizio Valeriani

Vitaliana De Sanctis

Luca Marinelli

Fabiola Cipolla

Ottavia De Luca

Maurizio Simmaco

Mattia F Osti

Affiliations

Soon will be listed here.

Abstract

Purpose: Standard treatment for locally advanced rectal cancer consists of neoadjuvant radiochemotherapy with concomitant fluoropyrimidine or oxaliplatin and surgery with curative intent. Pathological complete response has shown to be predictive for better outcome and survival; nevertheless there are no biological or genetic factors predictive for response to treatment. We explored the correlation between the single nucleotide polymorphisms (SNPs) GSTP1 (A313G) and XRCC1 (G28152A), and the pathological complete response and survival after neoadjuvant radiochemotherapy in locally advanced rectal cancer patients.

Materials And Methods: Genotypes GSTP1 (A313G) and XRCC1 (G28152A) were determined by pyrosequencing technology in 80 patients affected by locally advanced rectal cancer.

Results: The overall rate of pathological complete response in our study population was 18.75%. Patients homozygous AA for GSTP1 (A313G) presented a rate of pathological complete response of 26.6% as compared to 8.5% of the AG+GG population (p = 0.04). The heterozygous comparison (AA vs. AG) showed a significant difference in the rate of pathological complete response (26.6% vs. 6.8%; p = 0.034). GSTP1 AA+AG patients presented a 5- and 8-year cancer-specific survival longer than GSTP1 GG patients (87.7% and 83.3% vs. 44.4% and 44.4%, respectively) (p = 0.014). Overall survival showed only a trend toward significance in favor of the haplotypes GSTP1 AA+AG. No significant correlations were found for XRCC1 (G28152A).

Conclusion: Our results suggest that GSTP1 (A313G) may predict a higher rate of pathological complete response after neoadjuvant radiochemotherapy and a better outcome, and should be considered in a more extensive analysis with the aim of personalization of radiation treatment.

Citing Articles

Significant Association Between XRCC1 Expression and Its rs25487 Polymorphism and Radiotherapy-Related Cancer Prognosis.

Gong L, Luo M, Sun R, Qiu L, Chen C, Luo Z Front Oncol. 2021; 11:654784.

PMID: 34094945 PMC: 8170393. DOI: 10.3389/fonc.2021.654784.

Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy.

De Mattia E, Roncato R, Palazzari E, Toffoli G, Cecchin E Front Pharmacol. 2020; 11:897.

PMID: 32625092 PMC: 7311751. DOI: 10.3389/fphar.2020.00897.

Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer.

Yu J, Park H, Lee J, Choi C, Kang W, Park S Cancers (Basel). 2020; 12(4).

PMID: 32290335 PMC: 7226608. DOI: 10.3390/cancers12040943.

References

Zhang H, Wang M, Shi T, Shen L, Liang L, Deng Y . TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. Medicine (Baltimore). 2015; 94(45):e1955. PMC: 4912262. DOI: 10.1097/MD.0000000000001955. View

Janjan N, Khoo V, Abbruzzese J, Pazdur R, Dubrow R, Cleary K . Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 1999; 44(5):1027-38. DOI: 10.1016/s0360-3016(99)00099-1. View

Bosset J, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L . Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355(11):1114-23. DOI: 10.1056/NEJMoa060829. View

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

Edvardsen H, Kristensen V, Grenaker Alnaes G, Bohn M, Erikstein B, Helland A . Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 67(4):1163-71. DOI: 10.1016/j.ijrobp.2006.11.009. View

Bohanes P, Rankin C, Blanke C, Winder T, Ulrich C, Smalley S . Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res. 2015; 21(7):1583-90. PMC: 4566931. DOI: 10.1158/1078-0432.CCR-14-0857. View

Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset J, GONZALEZ D . Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and.... J Clin Oncol. 1997; 15(5):2040-9. DOI: 10.1200/JCO.1997.15.5.2040. View

Osti M, Nicosia L, Agolli L, Gentile G, Falco T, Bracci S . Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. Am J Clin Oncol. 2015; 40(6):535-542. DOI: 10.1097/COC.0000000000000182. View

Kim J, Kim J, Cho M, Song K, Yoon W . Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2002; 54(2):403-8. DOI: 10.1016/s0360-3016(02)02856-0. View

10.

Sweeney C, Nazar-Stewart V, Stapleton P, Eaton D, Vaughan T . Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2003; 12(6):527-33. View

11.

Wang Y, Spitz M, Zhu Y, Dong Q, Shete S, Wu X . From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst). 2003; 2(8):901-8. DOI: 10.1016/s1568-7864(03)00085-5. View

12.

Agostini M, Pasetto L, Pucciarelli S, Terrazzino S, Ambrosi A, Bedin C . Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy. Drugs Aging. 2008; 25(6):531-9. DOI: 10.2165/00002512-200825060-00006. View

13.

Kim D, Paek T, Oh S, Kim Y, Lee J, Lee M . Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer. J Surg Oncol. 2013; 109(3):250-4. DOI: 10.1002/jso.23500. View

14.

Losi L, Luppi G, Gavioli M, Iachetta F, Bertolini F, DAmico R . Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis. 2005; 21(7):645-51. DOI: 10.1007/s00384-005-0061-x. View

15.

Borchiellini D, Etienne-Grimaldi M, Thariat J, Milano G . The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. Cancer Treat Rev. 2012; 38(6):737-59. DOI: 10.1016/j.ctrv.2012.02.004. View

16.

Smith J, Wasserman I, Milgrom S, Chow O, Chen C, Patil S . Single Nucleotide Polymorphism TGFβ1 R25P Correlates with Acute Toxicity during Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. Int J Radiat Oncol Biol Phys. 2017; 97(5):924-930. PMC: 5389377. DOI: 10.1016/j.ijrobp.2016.12.015. View

17.

Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R . Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 2010; 11(3):214-26. DOI: 10.1038/tpj.2010.25. View

18.

Paez D, Salazar J, Pare L, Pertriz L, Targarona E, del Rio E . Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys. 2011; 81(5):1319-27. DOI: 10.1016/j.ijrobp.2011.01.025. View

19.

Wang J, Jiang J, Zhao Y, Gajalakshmi V, Kuriki K, Suzuki S . Genetic polymorphisms of glutathione S-transferase genes and susceptibility to colorectal cancer: a case-control study in an Indian population. Cancer Epidemiol. 2010; 35(1):66-72. DOI: 10.1016/j.canep.2010.07.003. View

20.

Okcu M, Selvan M, Wang L, Stout L, Erana R, Airewele G . Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res. 2004; 10(8):2618-25. DOI: 10.1158/1078-0432.ccr-03-0053. View